07 Jan 2001

Endoxan® (Endoxan® Dragees) - Deutschland

Updated: 07 Jan 2001

Endoxan®

Akute u. chronische lymphatische und myeloische Leukämien. Maligne Lymphome, z. B. M. Hodgkin, Non-Hodgkin-Lymphome, Plasmozytom. Maligne solide Tumoren, z. B. Ovarialkarzinom, Hodenkarzinom, Mammakarzinom, kleinzelliges Bronchialkarzinom, Neuroblastom, Ewing-Sarkom. Bedrohlich verlaufende Autoimmunkrankheiten wie z. B. rheumatoide Arthritis, Arthropathia psoriatica, systemischer Lupus erythematodes, Sklerodermie, systemische Vaskulitiden (auch mit nephrotischem Syndrom), bestimmte Formen der Glomerulonephritis (z. B. mit nephrotischem Syndrom), Myasthenia gravis, autoimmunhämolytische Anämie, Kälteagglutinationskrankheiten; bei immunsuppressiver Beh. bei Organtransplantation.

Endoxan® Description, Presentation and Dosage

Endoxan® Description

Endoxan® Drug Class Description

Cyclophosphamid

Endoxan® Drug Description

1 Drg. enth.: Cyclophosphamid 1H2O 53,5 mg (entspr. 50 mg Cyclophosphamid H2O-frei). Cyclophosphamid H2O-frei).

Endoxan® Generic Name

Endoxan® Dragees

Endoxan® Presentation

Endoxan® Presentation

Endoxan®

Endoxan® Manufacturer

ASTA Medica AWD

Related Learning Zones

Prostate Cancer Learning Hub

Prostate Cancer Learning Hub

The Prostate Cancer Learning Hub has been designed with the busy healthcare professional in mind. The resource conveniently organises a range of up-to-date education content, reference materials and decision support tools, all focussing on prostate cancer. The disease awareness section provides you with access to a Prostate Cancer Knowledge Centre, which has been developed to provide you with easy to digest best practice guidance for the treatment and management of patients with prostate cancer.

LAL-D Knowledge Centre

LAL-D Knowledge Centre

The Lysosomal Acid Lipase (LAL) Deficiency Knowledge Centre contains a range of accurate, informative clinical content for healthcare professionals. The disease awareness section presents epidemiology, pathophysiology and diagnosis information, among others. The treatment section details the drug characteristics, safety and efficacy of sebelipase alfa – the first and only licenced treatment for LAL deficiency. The resources section contains further clinical content including a video channel presenting expert opinions on diagnostic approach and current prognosis.

Developed by EPG Health Media (Europe) Ltd for epgonline.org, in collaboration and with content provided by Alexion Pharma GmbH

Endoxan® Dosage

Endoxan® Adult Dosage

Glycerol 85%, Magnesiumstearat, Talkum, Calciumhydrogenphosphat 2H2O, Lactose 1H2O, Maisstärke, Hoechst Wachs E Pharma, Polysorbat 20, Carmellose-Natrium, Povidon mittl. MG 29 000, Macrogol 35 000, Calciumcarbonat, Saccharose, Farbstoff E 171.

Endoxan® Child Dosage


Endoxan® Trockensubstanz iv., im. in Injektionsflaschen
Zus.: 1 Inj.-Fl. enth.: Cyclophosphamid 1H2O 106,9 mg/213,8 mg/534,5 mg/1069 mg (entspr. 100 mg/200 mg/500 mg/1000 mg
Weit. Bestandteile: Natriumchlorid 45 mg/90 mg/225 mg/450 mg.

Endoxan® Precautions, Reactions and Contraindications

Endoxan® Special Precautions

Endoxan® Special Precautions

C 110. Schwere Beeinträchtigung der Nierenfunktion. Abflußbehinderungen der ableitenden Harnwege, floride Infektionen. Akute hämorrhagische Zystitis.

Endoxan® Adverse Reactions

Endoxan® Adverse Reactions

C 110. 1. Trim: Kontraind./ bei vitaler Ind. ggf. Schwangerschaftsunterbrechung. 2. + 3. Trim.: Risikoaufklärung/Kontrazeption bei Ther. u. nach Abschluß (Dauer nach Prognose/Kinderwunsch). Männer: vor Ther. Beratung über Spermakonservierung.

Related Drugs - Oncology

Back to top